核医学装置市場 – 2030年までの世界予測

本レポートは、既存企業だけでなく新規参入企業や小規模企業にとっても、市場の動向を把握し、シェア拡大に役立てることができます。本レポートを購入した企業は、以下の5つの戦略のいずれか、または組み合わせて活用することができます。

核医学機器市場は2025年に66億3,000万米ドルと評価され、2030年には83億1,000万米ドルに達すると予測されており、予測期間中に4.62%の年平均成長率（CAGR）を記録します。がんや心血管疾患などの慢性疾患の罹患率の増加と、早期かつ正確な画像診断への需要の高まりが、核医学機器市場の成長を牽引しています。さらに、個別化医療への意識の高まり、放射線治療の適用拡大、政府の支援策、放射性医薬品へのアクセス改善なども、市場の成長に貢献しています。AIの統合やモバイル／リモートアクセスなどの技術革新は、診断効率を向上させ、市場プレーヤーに大きなビジネスチャンスをもたらすでしょう。

The nuclear medicine equipment market was valued at USD 6.63 billion in 2025 and is estimated to reach USD 8.31 billion by 2030, registering a CAGR of 4.62% during the forecast period. The growing prevalence of chronic diseases such as cancer and cardiovascular disorders, as well as the rising demand for early and accurate diagnostic imaging, are driving market growth in nuclear medicine equipment. Furthermore, increased awareness of personalized medicine, expanded applications of radiotheranostics, supportive government initiatives, and improved access to radiopharmaceuticals are all contributing to market growth. Technological innovations, such as AI integration and mobile/remote access, will improve diagnostic efficiency and create significant opportunities for market players.

The 3D segment dominated the nuclear medicine equipment market, by dimension, in 2024.

Based on dimension, the 3D segment is expected to hold the largest share of the nuclear medicine equipment market in 2024.  This is due to the superior imaging capabilities of 3D systems, which provide higher spatial resolution, greater anatomical detail, and more accurate localization of lesions than 2D imaging. These benefits are especially useful in oncology, cardiology, and neurology, where accurate visualization is essential for diagnosis, staging, and treatment planning. The growing adoption of advanced modalities such as PET/CT and SPECT/CT, which provide 3D imaging by default, combined with rising demand for quantitative imaging and personalized treatment approaches, contributes to the 3D segment’s dominance.

The North American market accounted for the largest share in the nuclear medicine equipment market in 2024.

The North American market dominated the nuclear medicine equipment market in 2024.  This dominance is accelerated by various factors such as advanced healthcare infrastructure and the widespread use of nuclear medicine procedures. The US National Academies (NCBI) report that nearly 20 million nuclear medicine procedures using radiopharmaceuticals and imaging instruments are carried out annually in the US alone, with increasing growth in hybrid PET/CT and SPECT/CT systems. Moreover, the rise in chronic diseases, especially cancer, which is predicted to account for over 2 million new cases and 6,12,000 deaths in the US by 2024, makes early and accurate diagnosis technologies even more crucial in North America. The main factors contributing to North America’s dominance in the global nuclear medicine equipment market are favorable reimbursement policies, substantial R&D spending by both the public and private sectors, and the presence of major industry players such as GE Healthcare, Siemens Healthineers, and Cardinal Health.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the nuclear medicine equipment marketplace.

The breakdown of primary participants is as mentioned below:

• By Company Type – Tier 1 (41%), Tier 2 (31%), and Tier 3 (28%)
• By Designation – C-level (44%), Directors (31%), and Others (25%)
• By Region – North America (45%), Europe (28%), Asia Pacific (20%), Latin America (4%), Middle East & Africa (3%)

Key Players in the Nuclear Medicine Equipment Market

Prominent players in the nuclear medicine equipment market include Hermes Medical Solutions (Sweden), DOSIsoft (France), Segami Corporation (US), GE HealthCare (US), Siemens Healthineers AG (Germany), Koninklijke Philips N.V. (Netherlands), Mirion Technologies, Inc. (US), Comecer S.p.A. (Italy), Syntermed (US), UltraSPECT Inc. (US), LabLogic Systems Ltd. (UK), Mediso Ltd. (Hungary), CANON MEDICAL SYSTEMS CORPORATION (Japan), Catalyst Medtech (US), Lemer Pax (France), Spectrum Dynamics Medical (US), Neusoft Medical Systems Co., Ltd. (China), Brainlab AG(Germany), Mirada Medical(UK), Trasis (Belgium), SOFIE (US), ITM Isotope Technologies Munich SE (Germany), Positrigo AG (Switzerland), PAIRE (France).

Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

The study includes an in-depth competitive analysis of these key players in the nuclear medicine equipment market, with their company profiles, recent developments, and key market strategies.

Research Coverage

• The report studies the nuclear medicine equipment market based on product type, therapeutic area, dimension, end user, and region.
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total nuclear medicine equipment market.
• The report forecasts the revenue of market segments with respect to five major regions.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the following five strategies.

This report provides insights into the following pointers:

Analysis of key drivers (rising prevalence of cancer and cardiovascular diseases, technological advancements in hybrid imaging systems, growing demand for personalized medicines and theranostics), restraints (high cost of nuclear medicine equipment and imaging procedures, limited availability and short shelf-life of radiopharmaceuticals), opportunities (development of novel radiotracers and targeted imaging agents, integration of AI and data analytics in imaging workflows), and challenges (stringent regulatory approval processes for equipment and radiopharmaceuticals, shortage of skilled nuclear medicine professionals, radioactive waste management and safety concerns) influencing the industry macro dynamics of nuclear medicine equipment market.

• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the nuclear medicine equipment market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of nuclear medicine equipment across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the nuclear medicine equipment market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the nuclear medicine equipment market.

Table of Contents

1           INTRODUCTION            34

1.1        STUDY OBJECTIVES      34

1.2        MARKET DEFINITION    34

1.3        STUDY SCOPE   35

1.3.1      MARKET SEGMENTATION AND REGIONAL SCOPE            35

1.3.2      INCLUSIONS AND EXCLUSIONS 36

1.3.3      YEARS CONSIDERED      36

1.4        CURRENCY CONSIDERED           37

1.5        STAKEHOLDERS            37

2           RESEARCH METHODOLOGY       38

2.1        RESEARCH APPROACH  38

2.1.1      SECONDARY RESEARCH            38

2.1.1.1   Key data from secondary sources            39

2.1.2      PRIMARY RESEARCH     40

2.1.2.1   Primary sources 40

2.1.2.2   Key data from primary sources    41

2.1.2.3   Breakdown of primary interviews             41

2.1.2.4   Insights from primary experts      42

2.2        RESEARCH METHODOLOGY       42

2.3        MARKET SIZE ESTIMATION       43

2.4        MARKET BREAKDOWN AND DATA TRIANGULATION            48

2.5        MARKET SHARE ESTIMATION   48

2.6        RESEARCH ASSUMPTIONS         49

2.7        RESEARCH LIMITATIONS          49

2.8        RISK ASSESSMENT        49

3           EXECUTIVE SUMMARY  50

4           PREMIUM INSIGHTS      54

4.1        OVERVIEW OF NUCLEAR MEDICINE EQUIPMENT MARKET           54

4.2        ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA        55

4.3        GEOGRAPHIC SNAPSHOT OF NUCLEAR MEDICINE EQUIPMENT MARKET    56

4.4        NUCLEAR MEDICINE EQUIPMENT MARKET: REGIONAL MIX       57

4.5        NUCLEAR MEDICINE EQUIPMENT MARKET: DEVELOPED VS. EMERGING MARKETS  57

5           MARKET OVERVIEW      58

5.1        INTRODUCTION            58

5.2        MARKET DYNAMICS      58

5.2.1      DRIVERS           60

5.2.1.1   Rapid expansion of theranostics   60

5.2.1.2   Technological advancements in hybrid imaging modalities            60

5.2.1.3   Favorable government support and expanding healthcare infrastructure     61

5.2.1.4   Advancements in radiotracers and radiopharmaceuticals            61

5.2.1.5   Integration of AI into nuclear medicine equipment 62

5.2.2      RESTRAINTS     62

5.2.2.1   Capital-intensive nature of equipment      62

5.2.2.2   Short half-life of radiopharmaceuticals     63

5.2.2.3   High maintenance and operational costs   63

5.2.2.4   Shortage of trained personnel      64

5.2.3      OPPORTUNITIES           64

5.2.3.1   Growing preference for personalized and precision medicine            64

5.2.3.2   Telemedicine and cloud-native platforms & mobile/remote imaging capabilities        65

5.2.4      CHALLENGES    65

5.2.4.1   Global isotope supply chain instability      65

5.2.4.2   Cybersecurity and data privacy issues in imaging IT            66

5.3        TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS         66

5.4        INDUSTRY TRENDS       67

5.4.1      SHIFT TOWARD HYBRID AND MULTI-MODALITY IMAGING SYSTEMS       67

5.4.2      ADVANCEMENTS IN DETECTOR TECHNOLOGIES AND IMAGE QUALITY            68

5.4.3      GROWING DEMAND FOR COMPACT AND VERSATILE SYSTEMS          68

5.4.4      INTEGRATION OF ARTIFICIAL INTELLIGENCE AND AUTOMATION   68

5.4.5      CONNECTIVITY AND CLOUD-ENABLED WORKFLOWS            68

5.5        PRICING ANALYSIS        68

5.5.1      INTRODUCTION            68

5.5.2     INDICATIVE PRICE OF NUCLEAR MEDICINE EQUIPMENT, BY KEY PLAYER            69

5.5.3     INDICATIVE PRICE OF NUCLEAR MEDICINE EQUIPMENT, BY REGION        70

5.5.4      AVERAGE SELLING PRICE OF NUCLEAR CARDIOLOGY REPORTING SOFTWARE            71

5.5.5      PRICING MODELS          72

5.6        VALUE CHAIN ANALYSIS           73

5.7        ECOSYSTEM ANALYSIS 75

5.8        INVESTMENT AND FUNDING SCENARIO            78

5.9        TECHNOLOGY ANALYSIS           78

5.9.1      KEY TECHNOLOGIES     78

5.9.1.1   Hybrid imaging systems  78

5.9.1.2   Digital detection technology        78

5.9.1.3   Artificial Intelligence (AI) and advanced image reconstruction techniques           79

5.9.1.4   Time-of-Flight (TOF) technology            79

5.9.1.5   Solid-state detector technology   79

5.9.2      COMPLEMENTARY TECHNOLOGIES       79

5.9.2.1   Radiopharmaceutical development and theranostics            79

5.9.2.2   Advanced computing and big data analytics           80

5.9.2.3   Robotics and automated dose dispensing systems  80

5.9.3      ADJACENT TECHNOLOGIES       80

5.9.3.1   Magnetic Resonance Imaging (MRI) integration      80

5.9.3.2   Computed Tomography (CT) advancements          80

5.10      PATENT ANALYSIS       81

5.11      TRADE ANALYSIS          82

5.11.1    IMPORT DATA FOR HS CODE 901814     83

5.11.2    EXPORT DATA FOR HS CODE 901814     84

5.12      KEY CONFERENCES AND EVENTS, 2025–2026   84

5.13      CASE STUDY ANALYSIS            85

5.13.1    PRECISION IN NUCLEAR MEDICINE WITH NATIONAL STANDARD TRACEABILITY       85

5.13.2    MULTI-MODALITY IMAGE FUSION FOR IMPROVED DIAGNOSTICS   86

5.13.3    REMOTE CONSULTATION WITH CLOUD-BASED NUCLEAR MEDICINE ANALYSIS 86

5.14      TARIFF AND REGULATORY LANDSCAPE            87

5.14.1    TARIFF DATA FOR HS CODE 901814      87

5.14.2    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           88

5.14.3    REGULATORY ANALYSIS           90

5.15      PORTER’S FIVE FORCES ANALYSIS        94

5.15.1    BARGAINING POWER OF SUPPLIERS      96

5.15.2    BARGAINING POWER OF BUYERS          96

5.15.3    THREAT OF NEW ENTRANTS    96

5.15.4    THREAT OF SUBSTITUTES       96

5.15.5    INTENSITY OF COMPETITIVE RIVALRY 96

5.16      KEY STAKEHOLDERS AND BUYING CRITERIA    97

5.16.1    KEY STAKEHOLDERS IN BUYING PROCESS        97

5.16.2    BUYING CRITERIA         98

5.17      END-USER ANALYSIS    98

5.17.1    UNMET NEEDS  98

5.17.2    END-USER EXPECTATIONS       99

5.18      BUSINESS MODEL         100

5.18.1    DIRECT EQUIPMENT SALES MODEL      100

5.18.2    SERVICE AND MAINTENANCE CONTRACTS       100

5.18.3    PAY-PER-SCAN (OR PAY-PER-USE) MODEL      101

5.18.4    EQUIPMENT LEASING AND FINANCING SOLUTIONS            101

5.18.5    INTEGRATED SOLUTIONS AND MANAGED SERVICES            101

5.18.6    SOFTWARE AND DATA ANALYTICS SUBSCRIPTION            101

5.19      IMPACT OF AI/GEN AI   101

5.19.1    INTRODUCTION            101

5.19.2    MARKET POTENTIAL OF AI/GEN AI       102

5.19.3    CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION        103

5.19.3.1 AI-based low-dose PET image reconstruction      103

5.19.3.2 Dose-aware diffusion models for 3D low-dose PET            103

5.19.4    IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS          104

5.19.4.1 Medical image analysis software  104

5.19.4.2 Radiology information systems     104

5.19.4.3 Clinical decision support systems             105

5.19.5    USER READINESS AND IMPACT ASSESSMENT   105

5.19.5.1 User readiness   105

5.19.5.1.1           User A: Hospitals           105

5.19.5.1.2           User B: Diagnostic imaging centers          105

5.19.5.2 Impact assessment         106

5.19.5.2.1           User A: Hospitals           106

5.19.5.2.2           User B: Diagnostic imaging centers          106

5.20      IMPACT OF 2025 US TARIFF – OVERVIEW         107

5.20.1    INTRODUCTION            107

5.20.2    KEY TARIFF RATES       107

5.20.3    PRICE IMPACT ANALYSIS          108

5.20.3.1 Capital equipment (cyclotrons, PET/SPECT systems)            108

5.20.3.2 Gamma cameras 108

5.20.3.3 Key materials: semiconductors, detectors, shielding            108

5.20.3.4 Service parts, maintenance, and global supply chains            108

5.20.4    IMPACT ON COUNTRY/REGION  109

5.20.4.1 US        109

5.20.4.2 Europe  109

5.20.4.3 Asia Pacific        109

5.20.5    IMPACT ON END-USE INDUSTRIES       110

5.20.5.1 Hospitals           110

5.20.5.2 Diagnostic imaging centers          110

5.20.5.3 Cancer treatment centers            110

5.20.5.4 Other end users  111

5.20.6    CONCLUSION    111

6           NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE    112

6.1        INTRODUCTION            113

6.2        IMAGING MODALITIES   113

6.2.1      PET      115

6.2.1.1   Standalone PET  116

6.2.1.1.1            Increasing demand for cost-efficient, high-throughput oncological imaging to boost market    116

6.2.1.2   Hybrid PET        117

6.2.1.2.1            Ability to provide functional and anatomical information in single scan to aid growth    117

6.2.2      SPECT  118

6.2.2.1   Standalone SPECT          120

6.2.2.1.1            Wide use in thyroid studies, renal scans, and bone imaging to encourage growth       120

6.2.2.2   Hybrid SPECT    121

6.2.2.2.1            Need for improved diagnostic accuracy and clinical confidence to propel market        121

6.2.3      GAMMA/SCINTILLATION CAMERAS       122

6.2.3.1   Clinical versatility and lower cost to expedite growth            122

6.3        NON-IMAGING MODALITIES      123

6.3.1      GM COUNTERS  124

6.3.1.1   Ease of use, portability, and critical role in maintaining workplace safety to spur growth  124

6.3.2      DOSE CALIBRATORS     126

6.3.2.1   Increasing development in digital interfaces, automatic isotope recognition, and real-time data logging to bolster growth            126

6.3.3      PROBE COUNTING SYSTEMS     127

6.3.3.1   Technological advancements in probe counting systems to contribute to growth       127

6.3.4      GAMMA WELL COUNTERS         128

6.3.4.1   Growing use of gamma well counters in laboratory-based applications to propel market       128

6.3.5      OTHER NON-IMAGING MODALITIES      129

7           NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA    131

7.1        INTRODUCTION            132

7.2        ONCOLOGY       132

7.2.1      IMPROVEMENTS IN IMAGING ACCURACY AND TREATMENT PLANNING TO STIMULATE GROWTH        132

7.3        NEUROLOGY     134

7.3.1      ESCALATING GLOBAL BURDEN OF NEURODEGENERATIVE DISORDERS AND OTHER NEUROLOGICAL CONDITIONS TO AID GROWTH 134

7.4        CARDIOLOGY     135

7.4.1      PERSISTENT GLOBAL BURDEN OF CARDIOVASCULAR DISEASES TO FACILITATE GROWTH     135

7.5        ORTHOPEDICS   137

7.5.1      GROWING PREVALENCE OF DEGENERATIVE JOINT DISEASES, SPORTS INJURIES, AND OSTEOPOROSIS TO BOOST MARKET           137

7.6        THYROID           138

7.6.1      GLOBAL PREVALENCE OF HYPER- AND HYPOTHYROIDISM AND THYROID CANCER TO AUGMENT GROWTH           138

7.7        OTHER THERAPEUTIC AREAS   140

8           NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION       141

8.1        INTRODUCTION            142

8.2        2D         142

8.2.1      WIDE AVAILABILITY, EASE OF INTEGRATION, AND ESTABLISHED PRESENCE IN CLINICAL WORKFLOW TO AID GROWTH           142

8.3        3D         143

8.3.1      GROWING RELIANCE ON ADVANCED IMAGING TECHNOLOGIES TO FUEL MARKET       143

9           NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER    145

9.1        INTRODUCTION            146

9.2        HOSPITALS       146

9.2.1      CONTINUOUS TECHNOLOGICAL ADVANCEMENTS TO FOSTER GROWTH          146

9.3        DIAGNOSTIC IMAGING CENTERS           147

9.3.1      GROWING DEMAND FOR EARLY AND PRECISE DIAGNOSIS TO DRIVE MARKET 147

9.4        CANCER TREATMENT CENTERS           148

9.4.1      ESCALATING GLOBAL INCIDENCE OF CANCER TO PROMOTE GROWTH       148

9.5        OTHER END USERS       150

10         NUCLEAR MEDICINE EQUIPMENT MARKET, BY REGION            152

10.1      INTRODUCTION            153

10.2      NORTH AMERICA          154

10.2.1    MACROECONOMIC OUTLOOK FOR NORTH AMERICA            154

10.2.2    US        159

10.2.2.1 Advancements in PET and SPECT equipment for personalized care to aid growth   159

10.2.3    CANADA           162

10.2.3.1 Increasing adoption of advanced imaging technologies to support growth   162

10.3      EUROPE            165

10.3.1    MACROECONOMIC OUTLOOK FOR EUROPE        166

10.3.2    GERMANY         170

10.3.2.1 Increasing adoption of hybrid imaging systems to spur growth   170

10.3.3    UK        173

10.3.3.1 Favorable clinical guidelines supporting wider use of PET-CT to fuel market           173

10.3.4    FRANCE            176

10.3.4.1 Shift to hybrid imaging to accelerate growth         176

10.3.5    ITALY   179

10.3.5.1 Robust network of scanners to facilitate growth    179

10.3.6    SPAIN   182

10.3.6.1 Growing integration of cutting-edge technologies into clinical practice to propel market 182

10.3.7    SWEDEN           185

10.3.7.1 Rapid shift toward PET procedures to accelerate growth            185

10.3.8    REST OF EUROPE          188

10.4      ASIA PACIFIC    191

10.4.1    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC            191

10.4.2    JAPAN   197

10.4.2.1 Ongoing innovations in equipment and growing reliance on nuclear imaging for accurate detection to drive market      197

10.4.3    CHINA   200

10.4.3.1 Rapid investments in medical infrastructure and technological advancements in image analysis to spur growth            200

10.4.4    INDIA    203

10.4.4.1 Substantial cancer and cardiovascular disease burden to encourage growth           203

10.4.5    SOUTH KOREA  206

10.4.5.1 Universal health coverage to bolster growth         206

10.4.6    AUSTRALIA       209

10.4.6.1 Strong diagnostic imaging network and widespread adoption of hybrid imaging technologies to contribute to growth            209

10.4.7    REST OF ASIA PACIFIC  212

10.5      MIDDLE EAST & AFRICA           215

10.5.1    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 216

10.5.2    GCC COUNTRIES           220

10.5.2.1 Growing healthcare needs and favorable government support to boost market  220

10.5.3    REST OF MIDDLE EAST & AFRICA         223

10.6      LATIN AMERICA            226

10.6.1    MACROECONOMIC OUTLOOK FOR LATIN AMERICA            226

10.6.2    BRAZIL  230

10.6.2.1 Healthcare modernization efforts to accelerate growth            230

10.6.3    MEXICO             233

10.6.3.1 Expanding healthcare infrastructure to bolster growth            233

10.6.4    REST OF LATIN AMERICA         236

11         COMPETITIVE LANDSCAPE       240

11.1      OVERVIEW        240

11.2      KEY PLAYER STRATEGIES         240

11.2.1    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE EQUIPMENT MARKET   241

11.3      REVENUE ANALYSIS, 2020–2024            243

11.4      MARKET SHARE ANALYSIS, 2024          243

11.4.1    POSITRON EMISSION TOMOGRAPHY (PET) EQUIPMENT            247

11.4.2    SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) EQUIPMENT    249

11.5      MARKET RANKING ANALYSIS    251

11.6      BRAND/PRODUCT COMPARISON            252

11.7      COMPANY VALUATION AND FINANCIAL METRICS            253

11.8      COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024            254

11.8.1    STARS  254

11.8.2    EMERGING LEADERS     254

11.8.3    PERVASIVE PLAYERS    254

11.8.4    PARTICIPANTS  254

11.8.5    COMPANY FOOTPRINT: KEY PLAYERS, 2024      256

11.8.5.1 Company footprint          256

11.8.5.2 Region footprint  257

11.8.5.3 System type footprint     258

11.8.5.4 Therapeutic area footprint           259

11.8.5.5 Dimension footprint        260

11.8.5.6 End-user footprint          261

11.9      COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024      262

11.9.1    PROGRESSIVE COMPANIES        262

11.9.2    RESPONSIVE COMPANIES          262

11.9.3    DYNAMIC COMPANIES   262

11.9.4    STARTING BLOCKS       262

11.9.5    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024      264

11.9.5.1 Detailed list of key startups/SMEs            264

11.9.5.2 Competitive benchmarking of startups/SMEs         264

11.10     COMPETITIVE SCENARIO          265

11.10.1  PRODUCT LAUNCHES AND APPROVALS            265

11.10.2  DEALS   266

11.10.3  EXPANSIONS     267

11.10.4  OTHER DEVELOPMENTS           268

12         COMPANY PROFILES     269

12.1      KEY PLAYERS   269

12.1.1    GE HEALTHCARE          269

12.1.1.1 Business overview          269

12.1.1.2 Products offered             270

12.1.1.3 Recent developments      272

12.1.1.3.1           Product launches and approvals   272

12.1.1.3.2           Deals     273

12.1.1.3.3           Expansions        275

12.1.1.4 MnM view          276

12.1.1.4.1           Right to win       276

12.1.1.4.2           Strategic choices            276

12.1.1.4.3           Weaknesses and competitive threats        276

12.1.2    SIEMENS HEALTHINEERS AG    277

12.1.2.1 Business overview          277

12.1.2.2 Products offered             278

12.1.2.3 Recent developments      281

12.1.2.3.1           Product launches and approvals   281

12.1.2.3.2           Deals     282

12.1.2.4 MnM view          283

12.1.2.4.1           Right to win       283

12.1.2.4.2           Strategic choices            283

12.1.2.4.3           Weaknesses and competitive threats        283

12.1.3    KONINKLIJKE PHILIPS N.V.       285

12.1.3.1 Business overview          285

12.1.3.2 Products offered             286

12.1.3.3 Recent developments      288

12.1.3.3.1           Product launches and approvals   288

12.1.3.3.2           Deals     289

12.1.3.4 MnM view          289

12.1.3.4.1           Right to win       289

12.1.3.4.2           Strategic choices            290

12.1.3.4.3           Weaknesses and competitive threats        290

12.1.4    MIRION TECHNOLOGIES, INC.    291

12.1.4.1 Business overview          291

12.1.4.2 Products offered             292

12.1.4.3 Recent developments      294

12.1.4.3.1           Product launches and approvals   294

12.1.4.3.2           Deals     294

12.1.4.4 MnM view          295

12.1.4.4.1           Right to win       295

12.1.4.4.2           Strategic choices            295

12.1.4.4.3           Weaknesses and competitive threats        295

12.1.5    CANON MEDICAL SYSTEMS CORPORATION       296

12.1.5.1 Business overview          296

12.1.5.2 Products offered             297

12.1.5.3 Recent developments      298

12.1.5.3.1           Deals     298

12.1.5.4 MnM view          298

12.1.5.4.1           Right to win       298

12.1.5.4.2           Strategic choices            298

12.1.5.4.3           Weaknesses and competitive threats        299

12.1.6    HERMES MEDICAL SOLUTIONS  300

12.1.6.1 Business overview          300

12.1.6.2 Products offered             300

12.1.6.3 Recent developments      301

12.1.6.3.1           Product launches and approvals   301

12.1.6.3.2           Deals     302

12.1.6.3.3           Other developments        303

12.1.7    DOSISOFT SA   304

12.1.7.1 Business overview          304

12.1.7.2 Products offered             304

12.1.7.3 Recent developments      305

12.1.7.3.1           Product launches and approvals   305

12.1.7.3.2           Deals     305

12.1.8    SEGAMI CORPORATION 306

12.1.8.1 Business overview          306

12.1.8.2 Products offered             306

12.1.9    WINKGEN MEDICAL SYSTEMS GMBH & CO. KG 307

12.1.9.1 Business overview          307

12.1.9.2 Products offered             307

12.1.9.3 Recent developments      308

12.1.9.3.1           Product launches and approvals   308

12.1.9.3.2           Deals     308

12.1.10  COMECER S.P.A.           309

12.1.10.1           Business overview          309

12.1.10.2           Products offered             310

12.1.10.3           Recent developments      312

12.1.10.3.1         Product launches and approvals   312

12.1.10.3.2         Deals     312

12.1.10.3.3         Expansions        313

12.1.11  SYNTERMED INC.          314

12.1.11.1           Business overview          314

12.1.11.2           Products offered             314

12.1.11.3           Recent developments      315

12.1.11.3.1         Deals     315

12.1.12  ULTRASPECT INC.        316

12.1.12.1           Business overview          316

12.1.12.2           Products offered             316

12.1.13  LABLOGIC SYSTEMS LTD.         317

12.1.13.1           Business overview          317

12.1.13.2           Products offered             318

12.1.13.3           Recent developments      320

12.1.13.3.1         Product launches and approvals   320

12.1.13.3.2         Deals     320

12.1.13.3.3         Expansions        321

12.1.14  MEDISO LTD.    322

12.1.14.1           Business overview          322

12.1.14.2           Products offered             323

12.1.14.3           Recent developments      324

12.1.14.3.1         Product launches and approvals   324

12.1.15  CATALYST MEDTECH   325

12.1.15.1           Business overview          325

12.1.15.2           Products offered             325

12.1.15.3           Recent developments      326

12.1.15.3.1         Deals     326

12.1.15.3.2         Other developments        327

12.1.16  LEMER PAX       328

12.1.16.1           Business overview          328

12.1.16.2           Products offered             328

12.1.16.3           Recent developments      329

12.1.16.3.1         Product launches and approvals   329

12.1.16.3.2         Deals     329

12.1.17  SPECTRUM DYNAMICS MEDICAL           331

12.1.17.1           Business overview          331

12.1.17.2           Products offered             331

12.1.17.3           Recent developments      332

12.1.17.3.1         Product launches and approvals   332

12.1.17.3.2         Deals     332

12.1.18  NEUSOFT MEDICAL SYSTEMS CO., LTD.            333

12.1.18.1           Business overview          333

12.1.18.2           Recent developments      335

12.1.18.2.1         Product launches and approvals   335

12.1.18.2.2         Deals     335

12.1.19  BRAINLAB SE   336

12.1.19.1           Business overview          336

12.1.19.2           Products offered             336

12.1.19.3           Recent developments      337

12.1.19.3.1         Product launches and approvals   337

12.1.19.3.2         Deals     338

12.1.20  MIRADA MEDICAL         339

12.1.20.1           Business overview          339

12.1.20.2           Products offered             339

12.1.20.3           Recent developments      340

12.1.20.3.1         Product launches and approvals   340

12.1.20.3.2         Deals     341

12.2      OTHER PLAYERS           342

12.2.1    TRASIS  342

12.2.2    SOFIE    343

12.2.3    ITM ISOTOPE TECHNOLOGIES MUNICH SE        344

12.2.4    POSITRIGO AG  345

12.2.5    PAIRE    346

13         APPENDIX         347

13.1      DISCUSSION GUIDE       347

13.2      KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL            352

13.3      CUSTOMIZATION OPTIONS        354

13.4      RELATED REPORTS       354

13.5      AUTHOR DETAILS         355

LIST OF TABLES

TABLE 1           NUCLEAR MEDICINE EQUIPMENT MARKET: INCLUSIONS AND EXCLUSIONS 36

TABLE 2           EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021–2024       37

TABLE 3           NUCLEAR MEDICINE EQUIPMENT MARKET: RESEARCH ASSUMPTIONS         49

TABLE 4           NUCLEAR MEDICINE EQUIPMENT MARKET: RISK ASSESSMENT        49

TABLE 5           NUCLEAR MEDICINE EQUIPMENT MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS       59

TABLE 6           INDICATIVE PRICE OF NUCLEAR MEDICINE EQUIPMENT, BY KEY PLAYER,

2024 (USD)        70

TABLE 7           INDICATIVE PRICE OF NUCLEAR MEDICINE EQUIPMENT, BY REGION, 2024 (USD)    71

TABLE 8           AVERAGE SELLING PRICE OF NUCLEAR CARDIOLOGY REPORTING SOFTWARE, 2024 (USD)         71

TABLE 9           NUCLEAR MEDICINE EQUIPMENT MARKET: ROLE OF COMPANIES IN ECOSYSTEM    77

TABLE 10          JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR NUCLEAR MEDICINE EQUIPMENT MARKET, 2025      81

TABLE 11          IMPORT DATA FOR HS CODE 901814, BY COUNTRY,

2020–2024 (USD THOUSAND)     83

TABLE 12          EXPORTS DATA FOR HS CODE 901814, BY COUNTRY,

2020–2024 (USD THOUSAND)     84

TABLE 13          NUCLEAR MEDICINE EQUIPMENT MARKET: KEY CONFERENCES AND EVENTS, 2025–2026           84

TABLE 14          TARIFF DATA FOR HS CODE 901814      87

TABLE 15          NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS            88

TABLE 16          EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          89

TABLE 17          ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS            90

TABLE 18          REGULATORY STANDARDS IN NUCLEAR MEDICINE         90

TABLE 19          REGULATORY REQUIREMENTS IN NORTH AMERICA          91

TABLE 20          REGULATORY REQUIREMENTS IN EUROPE            92

TABLE 21          REGULATORY REQUIREMENTS IN ASIA PACIFIC            92

TABLE 22          REGULATORY REQUIREMENTS IN LATIN AMERICA          94

TABLE 23          REGULATORY REQUIREMENTS IN MIDDLE EAST & AFRICA          94

TABLE 24          NUCLEAR MEDICINE EQUIPMENT MARKET: PORTER’S FIVE FORCES ANALYSIS        95

TABLE 25          INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)      97

TABLE 26          KEY BUYING CRITERIA FOR END USERS            98

TABLE 27          UNMET NEEDS IN NUCLEAR MEDICINE EQUIPMENT MARKET    99

TABLE 28          END-USER EXPECTATIONS IN NUCLEAR MEDICINE EQUIPMENT MARKET           100

TABLE 29          US ADJUSTED RECIPROCAL TARIFF RATES            107

TABLE 30          NUCLEAR MEDICINE EQUIPMENT, BY SYSTEM TYPE, 2023–2030 (USD MILLION)           113

TABLE 31          NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)            114

TABLE 32          NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY REGION, 2023–2030 (USD MILLION)            114

TABLE 33          NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (UNITS)     114

TABLE 34          PET EQUIPMENT OFFERED BY MAJOR PLAYERS            115

TABLE 35          NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         115

TABLE 36          NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY REGION,

2023–2030 (USD MILLION)         116

TABLE 37          NUCLEAR MEDICINE EQUIPMENT MARKET FOR STANDALONE PET, BY REGION, 2023–2030 (USD MILLION)            117

TABLE 38          NUCLEAR MEDICINE EQUIPMENT MARKET FOR HYBRID PET, BY REGION,

2023–2030 (USD MILLION)         118

TABLE 39          SPECT EQUIPMENT OFFERED BY MAJOR PLAYERS           119

TABLE 40          NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         119

TABLE 41          NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY REGION,

2023–2030 (USD MILLION)         120

TABLE 42          NUCLEAR MEDICINE EQUIPMENT MARKET FOR STANDALONE SPECT, BY REGION, 2023–2030 (USD MILLION)            121

TABLE 43          NUCLEAR MEDICINE EQUIPMENT MARKET FOR HYBRID SPECT, BY REGION,

2023–2030 (USD MILLION)         122

TABLE 44          GAMMA/SCINTILLATION CAMERAS OFFERED BY MAJOR PLAYERS      122

TABLE 45          NUCLEAR MEDICINE EQUIPMENT MARKET FOR GAMMA/SCINTILLATION CAMERAS, BY REGION, 2023–2030 (USD MILLION)  123

TABLE 46          NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      124

TABLE 47          NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES,

BY REGION, 2023–2030 (USD MILLION)  124

TABLE 48          GM COUNTERS OFFERED BY MAJOR PLAYERS            125

TABLE 49          NUCLEAR MEDICINE EQUIPMENT MARKET FOR GM COUNTERS, BY REGION, 2023–2030 (USD MILLION) 125

TABLE 50          DOSE CALIBRATORS OFFERED BY MAJOR PLAYERS           126

TABLE 51          NUCLEAR MEDICINE EQUIPMENT MARKET FOR DOSE CALIBRATORS, BY REGION, 2023–2030 (USD MILLION)            127

TABLE 52          PROBE COUNTING SYSTEMS OFFERED BY MAJOR PLAYERS           128

TABLE 53          NUCLEAR MEDICINE EQUIPMENT MARKET FOR PROBE COUNTING SYSTEMS,

BY REGION, 2023–2030 (USD MILLION)  128

TABLE 54          GAMMA WELL COUNTERS OFFERED BY MAJOR PLAYERS           129

TABLE 55          NUCLEAR MEDICINE EQUIPMENT MARKET FOR GAMMA WELL COUNTERS,

BY REGION, 2023–2030 (USD MILLION)  129

TABLE 56          NUCLEAR MEDICINE EQUIPMENT MARKET FOR OTHER NON-IMAGING MODALITIES, BY REGION, 2023–2030 (USD MILLION)  130

TABLE 57          NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)         132

TABLE 58          NUCLEAR MEDICINE EQUIPMENT FOR ONCOLOGY OFFERED BY MAJOR PLAYERS        133

TABLE 59          NUCLEAR MEDICINE EQUIPMENT MARKET FOR ONCOLOGY, BY REGION,

2023–2030 (USD MILLION)         134

TABLE 60          NUCLEAR MEDICINE EQUIPMENT FOR NEUROLOGY OFFERED BY MAJOR PLAYERS      135

TABLE 61          NUCLEAR MEDICINE EQUIPMENT MARKET FOR NEUROLOGY, BY REGION,

2023–2030 (USD MILLION)         135

TABLE 62          NUCLEAR MEDICINE EQUIPMENT FOR CARDIOLOGY OFFERED BY MAJOR PLAYERS      136

TABLE 63          NUCLEAR MEDICINE EQUIPMENT MARKET FOR CARDIOLOGY, BY REGION,

2023–2030 (USD MILLION)         137

TABLE 64          NUCLEAR MEDICINE EQUIPMENT FOR ORTHOPEDICS OFFERED BY MAJOR PLAYERS    138

TABLE 65          NUCLEAR MEDICINE EQUIPMENT MARKET FOR ORTHOPEDICS, BY REGION,

2023–2030 (USD MILLION)         138

TABLE 66          NUCLEAR MEDICINE EQUIPMENT FOR THYROID OFFERED BY MAJOR PLAYERS   139

TABLE 67          NUCLEAR MEDICINE EQUIPMENT MARKET FOR THYROID, BY REGION,

2023–2030 (USD MILLION)         139

TABLE 68          NUCLEAR MEDICINE EQUIPMENT MARKET FOR OTHER THERAPEUTIC AREAS,

BY REGION, 2023–2030 (USD MILLION)  140

TABLE 69          NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         142

TABLE 70          NUCLEAR MEDICINE 2D EQUIPMENT OFFERED BY MAJOR PLAYERS      142

TABLE 71          NUCLEAR MEDICINE 2D EQUIPMENT MARKET, BY REGION,

2023–2030 (USD MILLION)         143

TABLE 72          NUCLEAR MEDICINE 3D EQUIPMENT OFFERED BY MAJOR PLAYERS      144

TABLE 73          NUCLEAR MEDICINE 3D EQUIPMENT MARKET, BY REGION,

2023–2030 (USD MILLION)         144

TABLE 74          NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         146

TABLE 75          NUCLEAR MEDICINE EQUIPMENT FOR HOSPITALS OFFERED BY MAJOR PLAYERS        147

TABLE 76          NUCLEAR MEDICINE EQUIPMENT MARKET FOR HOSPITALS, BY REGION,

2023–2030 (USD MILLION)         147

TABLE 77          NUCLEAR MEDICINE EQUIPMENT FOR DIAGNOSTIC IMAGING CENTERS OFFERED BY MAJOR PLAYERS            148

TABLE 78          NUCLEAR MEDICINE EQUIPMENT MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2023–2030 (USD MILLION)           148

TABLE 79          NUCLEAR MEDICINE EQUIPMENT FOR CANCER TREATMENT CENTERS OFFERED

BY MAJOR PLAYERS      149

TABLE 80          NUCLEAR MEDICINE EQUIPMENT MARKET FOR CANCER TREATMENT CENTERS,

BY REGION, 2023–2030 (USD MILLION)  150

TABLE 81          NUCLEAR MEDICINE EQUIPMENT FOR OTHER END USERS OFFERED BY MAJOR PLAYERS        151

TABLE 82          NUCLEAR MEDICINE EQUIPMENT MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)            151

TABLE 83          NUCLEAR MEDICINE EQUIPMENT MARKET, BY REGION,

2023–2030 (USD MILLION)         153

TABLE 84          NORTH AMERICA: KEY MACROECONOMIC INDICATORS      155

TABLE 85          NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY COUNTRY,

2023–2030 (USD MILLION)         156

TABLE 86          NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION)           156

TABLE 87          NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)         156

TABLE 88          NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION)           157

TABLE 89          NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION)           157

TABLE 90          NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           157

TABLE 91          NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)           158

TABLE 92          NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION)           158

TABLE 93          NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION)            158

TABLE 94          US: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         159

TABLE 95          US: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      160

TABLE 96          US: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         160

TABLE 97          US: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         160

TABLE 98          US: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      161

TABLE 99          US: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)         161

TABLE 100        US: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         161

TABLE 101        US: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         162

TABLE 102        CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         163

TABLE 103        CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      163

TABLE 104        CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         163

TABLE 105        CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         164

TABLE 106        CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)  164

TABLE 107        CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            164

TABLE 108        CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         165

TABLE 109        CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         165

TABLE 110        EUROPE: KEY MACROECONOMIC INDICATORS            166

TABLE 111        EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY COUNTRY,

2023–2030 (USD MILLION)         167

TABLE 112        EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         167

TABLE 113        EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      167

TABLE 114        EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         168

TABLE 115        EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         168

TABLE 116        EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE 2023–2030 (USD MILLION)  168

TABLE 117        EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            169

TABLE 118        EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         169

TABLE 119        EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         169

TABLE 120        GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         170

TABLE 121        GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           170

TABLE 122        GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         171

TABLE 123        GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         171

TABLE 124        GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)  171

TABLE 125        GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            172

TABLE 126        GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         172

TABLE 127        GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         172

TABLE 128        UK: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         173

TABLE 129        UK: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      173

TABLE 130        UK: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         174

TABLE 131        UK: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         174

TABLE 132        UK: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      174

TABLE 133        UK: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)         175

TABLE 134        UK: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)        175

TABLE 135        UK: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         175

TABLE 136        FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         176

TABLE 137        FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      176

TABLE 138        FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         177

TABLE 139        FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         177

TABLE 140        FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)  177

TABLE 141        FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            178

TABLE 142        FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         178

TABLE 143        FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         178

TABLE 144        ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         179

TABLE 145        ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           179

TABLE 146        ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         180

TABLE 147        ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         180

TABLE 148        ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)  180

TABLE 149        ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)         181

TABLE 150        ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         181

TABLE 151        ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         181

TABLE 152        SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         182

TABLE 153        SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      182

TABLE 154        SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         183

TABLE 155        SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         183

TABLE 156        SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)  183

TABLE 157        SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)         184

TABLE 158        SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         184

TABLE 159        SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         184

TABLE 160        SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         185

TABLE 161        SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           185

TABLE 162        SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         186

TABLE 163        SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         186

TABLE 164        SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)  186

TABLE 165        SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            187

TABLE 166        SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         187

TABLE 167        SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         187

TABLE 168        REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION)           188

TABLE 169        REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)         188

TABLE 170        REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION)           189

TABLE 171        REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION)           189

TABLE 172        REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           189

TABLE 173        REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)           190

TABLE 174        REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION)           190

TABLE 175        REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION)            190

TABLE 176        ASIA PACIFIC: KEY MACROECONOMIC INDICATORS      192

TABLE 177        ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY COUNTRY,

2023–2030 (USD MILLION)         194

TABLE 178        ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         194

TABLE 179        ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           194

TABLE 180        ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION)            195

TABLE 181        ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         195

TABLE 182        ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)  195

TABLE 183        ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            196

TABLE 184        ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         196

TABLE 185        ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         196

TABLE 186        JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         197

TABLE 187        JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      197

TABLE 188        JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         198

TABLE 189        JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         198

TABLE 190        JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)  198

TABLE 191        JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)         199

TABLE 192        JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         199

TABLE 193        JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         199

TABLE 194        CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         200

TABLE 195        CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      201

TABLE 196        CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         201

TABLE 197        CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         201

TABLE 198        CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)  202

TABLE 199        CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)         202

TABLE 200        CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         203

TABLE 201        CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         203

TABLE 202        INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         204

TABLE 203        INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      204

TABLE 204        INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         204

TABLE 205        INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         205

TABLE 206        INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)  205

TABLE 207        INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)         205

TABLE 208        INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         206

TABLE 209        INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         206

TABLE 210        SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION)           207

TABLE 211        SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE 2023–2030 (USD MILLION)         207

TABLE 212        SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION)           207

TABLE 213        SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION)           208

TABLE 214        SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           208

TABLE 215        SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)           208

TABLE 216        SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         209

TABLE 217        SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         209

TABLE 218        AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         210

TABLE 219        AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           210

TABLE 220        AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION)            210

TABLE 221        AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         211

TABLE 222        AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)  211

TABLE 223        AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            211

TABLE 224        AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         212

TABLE 225        AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         212

TABLE 226        REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION)           213

TABLE 227        REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)         213

TABLE 228        REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT,

BY TYPE, 2023–2030 (USD MILLION)      213

TABLE 229        REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET,

BY TYPE, 2023–2030 (USD MILLION)      214

TABLE 230        REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           214

TABLE 231        REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET,

BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)      214

TABLE 232        REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION)           215

TABLE 233        REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION)            215

TABLE 234        MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS             216

TABLE 235        MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION)            217

TABLE 236        MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION)           217

TABLE 237        MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)         217

TABLE 238        MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT,

BY TYPE, 2023–2030 (USD MILLION)      218

TABLE 239        MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET,

BY TYPE, 2023–2030 (USD MILLION)      218

TABLE 240        MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR

NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           218

TABLE 241        MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET,

BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)      219

TABLE 242        MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET,

BY DIMENSION, 2023–2030 (USD MILLION)         219

TABLE 243        MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION)            219

TABLE 244        GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION)           220

TABLE 245        GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)         221

TABLE 246        GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION)           221

TABLE 247        GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION)           221

TABLE 248        GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           222

TABLE 249        GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)           222

TABLE 250        GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION)           222

TABLE 251        GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         223

TABLE 252        REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET,

BY SYSTEM TYPE, 2023–2030 (USD MILLION)    223

TABLE 253        REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           224

TABLE 254        REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION)      224

TABLE 255        REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION)  224

TABLE 256        REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)         225

TABLE 257        REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET,

BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)      225

TABLE 258        REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET,

BY DIMENSION, 2023–2030 (USD MILLION)         225

TABLE 259        REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET,

BY END USER, 2023–2030 (USD MILLION)          226

TABLE 260        LATIN AMERICA: KEY MACROECONOMIC INDICATORS      227

TABLE 261        LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY COUNTRY,

2023–2030 (USD MILLION)         227

TABLE 262        LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION)           227

TABLE 263        LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)         228

TABLE 264        LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION)           228

TABLE 265        LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION)           228

TABLE 266        LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           229

TABLE 267        LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)           229

TABLE 268        LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION)           229

TABLE 269        LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         230

TABLE 270        BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         230

TABLE 271        BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      231

TABLE 272        BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         231

TABLE 273        BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         231

TABLE 274        BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)  232

TABLE 275        BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)         232

TABLE 276        BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         232

TABLE 277        BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         233

TABLE 278        MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2023–2030 (USD MILLION)         234

TABLE 279        MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES,

BY TYPE, 2023–2030 (USD MILLION)      234

TABLE 280        MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE,

2023–2030 (USD MILLION)         234

TABLE 281        MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE,

2023–2030 (USD MILLION)         235

TABLE 282        MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE 2023–2030 (USD MILLION)  235

TABLE 283        MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            235

TABLE 284        MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2023–2030 (USD MILLION)         236

TABLE 285        MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2023–2030 (USD MILLION)         236

TABLE 286        REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION)           237

TABLE 287        REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)         237

TABLE 288        REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION)           237

TABLE 289        REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET,

BY TYPE, 2023–2030 (USD MILLION)      238

TABLE 290        REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR

NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION)           238

TABLE 291        REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET,

BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)      238

TABLE 292        REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET,

BY DIMENSION, 2023–2030 (USD MILLION)         239

TABLE 293        REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET,

BY END USER, 2023–2030 (USD MILLION)          239

TABLE 294        OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE EQUIPMENT MARKET, JANUARY 2022–JUNE 2025         241

TABLE 295        NUCLEAR MEDICINE EQUIPMENT MARKET: DEGREE OF COMPETITION        245

TABLE 296        POSITRON EMISSION TOMOGRAPHY (PET) EQUIPMENT MARKET: DEGREE OF COMPETITION         247

TABLE 297        SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) EQUIPMENT MARKET: DEGREE OF COMPETITION   249

TABLE 298        NUCLEAR MEDICINE EQUIPMENT MARKET: REGION FOOTPRINT      257

TABLE 299        NUCLEAR MEDICINE EQUIPMENT MARKET: SYSTEM TYPE FOOTPRINT        258

TABLE 300        NUCLEAR MEDICINE EQUIPMENT MARKET: THERAPEUTIC AREA FOOTPRINT          259

TABLE 301        NUCLEAR MEDICINE EQUIPMENT MARKET: DIMENSION FOOTPRINT            260

TABLE 302        NUCLEAR MEDICINE EQUIPMENT MARKET: END-USER FOOTPRINT 261

TABLE 303        NUCLEAR MEDICINE EQUIPMENT MARKET: DETAILED LIST OF KEY STARTUPS/SMES         264

TABLE 304        NUCLEAR MEDICINE EQUIPMENT MARKET: COMPETITIVE BENCHMARKING OF SMES/STARTUPS    264

TABLE 305        NUCLEAR MEDICINE EQUIPMENT MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025      265

TABLE 306        NUCLEAR MEDICINE EQUIPMENT MARKET: DEALS, JANUARY 2022–JUNE 2025        266

TABLE 307        NUCLEAR MEDICINE EQUIPMENT MARKET: EXPANSIONS,

JANUARY 2022–JUNE 2025         267

TABLE 308        NUCLEAR MEDICINE EQUIPMENT MARKET: OTHER DEVELOPMENTS,

JANUARY 2022–JUNE 2025         268

TABLE 309        GE HEALTHCARE: COMPANY OVERVIEW            269

TABLE 310        GE HEALTHCARE: PRODUCTS OFFERED            270

TABLE 311        GE HEALTHCARE: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025         272

TABLE 312        GE HEALTHCARE: DEALS, JANUARY 2022–JUNE 2025      273

TABLE 313        GE HEALTHCARE: EXPANSIONS, JANUARY 2022–JUNE 2025            275

TABLE 314        SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW        277

TABLE 315        SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED          278

TABLE 316        SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025         281

TABLE 317        SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–JUNE 2025            282

TABLE 318        KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW        285

TABLE 319        KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED          286

TABLE 320        KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025         288

TABLE 321        KONINKLIJKE PHILIPS N.V: DEALS, JANUARY 2022–JUNE 2025            289

TABLE 322        MIRION TECHNOLOGIES, INC.: COMPANY OVERVIEW        291

TABLE 323        MIRION TECHNOLOGIES, INC.: PRODUCTS OFFERED          292

TABLE 324        MIRION TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025         294

TABLE 325        MIRION TECHNOLOGIES, INC.: DEALS, JANUARY 2022–JUNE 2025            294

TABLE 326        CANON MEDICAL SYSTEMS CORPORATION: COMPANY OVERVIEW    296

TABLE 327        CANON MEDICAL SYSTEMS CORPORATION: PRODUCTS OFFERED    297

TABLE 328        CANON MEDICAL SYSTEMS CORPORATION: DEALS, JANUARY 2022–JUNE 2025        298

TABLE 329        HERMES MEDICAL SOLUTIONS: COMPANY OVERVIEW        300

TABLE 330        HERMES MEDICAL SOLUTIONS: PRODUCTS OFFERED          300

TABLE 331        HERMES MEDICAL SOLUTIONS: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025         301

TABLE 332        HERMES MEDICAL SOLUTIONS: DEALS, JANUARY 2022–JUNE 2025         302

TABLE 333        HERMES MEDICAL SOLUTIONS: OTHER DEVELOPMENTS,

JANUARY 2022–JUNE 2025         303

TABLE 334        DOSISOFT SA: COMPANY OVERVIEW     304

TABLE 335        DOSISOFT SA: PRODUCTS OFFERED      304

TABLE 336        DOSISOFT SA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025            305

TABLE 337        DOSISOFT SA: DEALS, JANUARY 2022–JUNE 2025      305

TABLE 338        SEGAMI CORPORATION: COMPANY OVERVIEW            306

TABLE 339        SEGAMI CORPORATION: PRODUCTS OFFERED            306

TABLE 340        WINKGEN MEDICAL SYSTEMS GMBH & CO. KG: COMPANY OVERVIEW    307

TABLE 341        WINKGEN MEDICAL SYSTEMS GMBH & CO. KG: PRODUCTS OFFERED    307

TABLE 342        WINKGEN MEDICAL SYSTEMS GMBH & CO. KG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025      308

TABLE 343        WINKGEN MEDICAL SYSTEMS GMBH & CO. KG: DEALS,

JANUARY 2022–JUNE 2025         308

TABLE 344        COMECER S.P.A.: COMPANY OVERVIEW            309

TABLE 345        COMECER S.P.A.: PRODUCTS OFFERED  310

TABLE 346        COMECER S.P.A.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025         312

TABLE 347        COMECER S.P.A.: DEALS, JANUARY 2022–JUNE 2025      312

TABLE 348        COMECER S.P.A.: EXPANSIONS, JANUARY 2022–JUNE 2025         313

TABLE 349        SYNTERMED INC.: COMPANY OVERVIEW            314

TABLE 350        SYNTERMED INC.: PRODUCTS OFFERED            314

TABLE 351        SYNTERMED INC.: DEALS, JANUARY 2022–JUNE 2025      315

TABLE 352        ULTRASPECT INC.: PRODUCTS OFFERED            316

TABLE 353        LABLOGIC SYSTEMS LTD.: COMPANY OVERVIEW        317

TABLE 354        LABLOGIC SYSTEMS LTD.: PRODUCTS OFFERED            318

TABLE 355        LABLOGIC SYSTEMS LTD.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025         320

TABLE 356        LABLOGIC SYSTEMS LTD.: DEALS, JANUARY 2022–JUNE 2025            320

TABLE 357        LABLOGIC SYSTEMS LTD.: EXPANSIONS, JANUARY 2022–JUNE 2025         321

TABLE 358        MEDISO LTD.: COMPANY OVERVIEW     322

TABLE 359        MEDISO LTD.: PRODUCTS OFFERED      323

TABLE 360        MEDISO LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025            324

TABLE 361        CATALYST MEDTECH: COMPANY OVERVIEW            325

TABLE 362        CATALYST MEDTECH: PRODUCTS OFFERED            325

TABLE 363        CATALYST MEDTECH: DEALS, JANUARY 2022–JUNE 2025         326

TABLE 364       CATALYST MEDTECH: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025         327

TABLE 365        LEMER PAX: COMPANY OVERVIEW        328

TABLE 366        LEMER PAX: PRODUCTS OFFERED         328

TABLE 367        LEMER PAX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025            329

TABLE 368        LEMER PAX: DEALS, JANUARY 2022–JUNE 2025            329

TABLE 369        SPECTRUM DYNAMICS MEDICAL: COMPANY OVERVIEW        331

TABLE 370        SPECTRUM DYNAMICS MEDICAL: PRODUCTS OFFERED          331

TABLE 371        SPECTRUM DYNAMICS MEDICAL: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025         332

TABLE 372        SPECTRUM DYNAMICS MEDICAL: DEALS, JANUARY 2022–JUNE 2025         332

TABLE 373        NEUSOFT MEDICAL SYSTEMS CO., LTD.: COMPANY OVERVIEW    333

TABLE 374        NEUSOFT MEDICAL SYSTEMS CO., LTD.: PRODUCTS OFFERED    334

TABLE 375        NEUSOFT MEDICAL SYSTEMS CO., LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025      335

TABLE 376        NEUSOFT MEDICAL SYSTEMS CO., LTD.: DEALS, JANUARY 2022–JUNE 2025         335

TABLE 377        BRAINLAB SE: COMPANY OVERVIEW     336

TABLE 378        BRAINLAB SE: PRODUCTS OFFERED      336

TABLE 379        BRAINLAB SE: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025            337

TABLE 380        BRAINLAB SE: DEALS, JANUARY 2022–JUNE 2025      338

TABLE 381        MIRADA MEDICAL: COMPANY OVERVIEW            339

TABLE 382        MIRADA MEDICAL: PRODUCTS OFFERED            339

TABLE 383        MIRADA MEDICAL: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025         340

TABLE 384        MIRADA MEDICAL: DEALS, JANUARY 2022–JUNE 2025      341

TABLE 385        TRASIS: COMPANY OVERVIEW  342

TABLE 386        SOFIE: COMPANY OVERVIEW     343

TABLE 387        ITM ISOTOPE TECHNOLOGIES MUNICH SE: COMPANY OVERVIEW    344

TABLE 388        POSITRIGO AG: COMPANY OVERVIEW   345

TABLE 389        PAIRE: COMPANY OVERVIEW    346

LIST OF FIGURES

FIGURE 1          NUCLEAR MEDICINE EQUIPMENT MARKET SEGMENTATION AND REGIONAL SCOPE           35

FIGURE 2          RESEARCH DESIGN        38

FIGURE 3          BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION   41

FIGURE 4          RESEARCH METHODOLOGY: HYPOTHESIS BUILDING          43

FIGURE 5          BOTTOM-UP APPROACH           44

FIGURE 6          TOP-DOWN APPROACH 45

FIGURE 7          CAGR PROJECTIONS FROM ANALYSIS OF MARKET DYNAMICS      46

FIGURE 8          CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS            46

FIGURE 9          DATA TRIANGULATION METHODOLOGY            48

FIGURE 10         NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE,

2025 VS. 2030 (USD MILLION)    50

FIGURE 11         NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION,

2025 VS. 2030 (USD MILLION)    51

FIGURE 12         NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA,

2025 VS. 2030 (USD MILLION)    51

FIGURE 13         NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)    52

FIGURE 14         NUCLEAR MEDICINE EQUIPMENT MARKET: REGIONAL SNAPSHOT   52

FIGURE 15         GROWING ADOPTION OF ADVANCED IMAGING MODALITIES AND EXPANSION OF THERANOSTICS TO DRIVE MARKET           54

FIGURE 16         ONCOLOGY SEGMENT AND JAPAN LED ASIA PACIFIC MARKET IN 2024          55

FIGURE 17         INDIA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD        56

FIGURE 18         ASIA PACIFIC TO DOMINATE MARKET DURING FORECAST PERIOD        57

FIGURE 19         EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD    57

FIGURE 20         NUCLEAR MEDICINE EQUIPMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES            58

FIGURE 21         REVENUE SHIFT AND NEW REVENUE POCKETS IN NUCLEAR MEDICINE EQUIPMENT MARKET   67

FIGURE 22         AVERAGE SELLING PRICE OF NUCLEAR CARDIOLOGY REPORTING SOFTWARE, 2024 (USD)         72

FIGURE 23         NUCLEAR MEDICINE EQUIPMENT MARKET: VALUE CHAIN ANALYSIS           75

FIGURE 24         NUCLEAR MEDICINE EQUIPMENT MARKET: ECOSYSTEM ANALYSIS 76

FIGURE 25         INVESTMENT AND FUNDING SCENARIO, 2015–2025      78

FIGURE 26         NUCLEAR MEDICINE EQUIPMENT MARKET: PATENT ANALYSIS, 2015–2025  82

FIGURE 27         NUCLEAR MEDICINE EQUIPMENT MARKET: PORTER’S FIVE FORCES ANALYSIS        95

FIGURE 28         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER           97

FIGURE 29         KEY BUYING CRITERIA FOR END USERS            98

FIGURE 30         MARKET POTENTIAL OF AI/GEN AI ON NUCLEAR MEDICINE EQUIPMENT ACROSS INDUSTRIES            102

FIGURE 31         IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS  104

FIGURE 32         NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET SNAPSHOT, 2024            155

FIGURE 33         ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET SNAPSHOT, 2024        193

FIGURE 34         REVENUE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE EQUIPMENT MARKET, 2020–2024  243

FIGURE 35         NUCLEAR MEDICINE EQUIPMENT MARKET SHARE ANALYSIS OF

KEY PLAYERS, 2024      244

FIGURE 36         POSITRON EMISSION TOMOGRAPHY (PET) EQUIPMENT MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024            247

FIGURE 37         SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) EQUIPMENT MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 249

FIGURE 38         MARKET RANKING ANALYSIS OF KEY PLAYERS, 2024      251

FIGURE 39         NUCLEAR MEDICINE EQUIPMENT MARKET: BRAND/PRODUCT COMPARISON            252

FIGURE 40         EV/EBITDA OF KEY VENDORS   253

FIGURE 41         YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA        253

FIGURE 42         NUCLEAR MEDICINE EQUIPMENT MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024            255

FIGURE 43         NUCLEAR MEDICINE EQUIPMENT MARKET: COMPANY FOOTPRINT  256

FIGURE 44         NUCLEAR MEDICINE EQUIPMENT MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024            263

FIGURE 45         GE HEALTHCARE: COMPANY SNAPSHOT (2024)            270

FIGURE 46         SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)         278

FIGURE 47         KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024)         286

FIGURE 48         MIRION TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)         292

FIGURE 49         CANON MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2024)     297

FIGURE 50         NEUSOFT MEDICAL SYSTEMS CO., LTD.: COMPANY SNAPSHOT (2024)     334

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧